Barnett & Company’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-880
Closed -$2K 315
2020
Q3
$2K Sell
880
-1,200
-58% -$3.43K ﹤0.01% 282
2020
Q2
$7K Sell
2,080
-425
-17% -$1.53K 0.01% 239
2020
Q1
$10K Hold
2,505
0.01% 256
2019
Q4
$8K Buy
+2,505
New +$6.51K ﹤0.01% 348

Other funds holding BMY.RT

Barnett & Company's BMY.RT Position: Q4 2020 in Review

Barnett & Company sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 880 shares — an estimated $2K sold.

Barnett & Company first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $10K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Barnett & Company reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Barnett & Company sold 880 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $2K.
  • Barnett & Company first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Barnett & Company's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $10K in Q1 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Barnett & Company's 13F filing for Q4 2020, filed 12 Feb 2021.